Overview

Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.

Status:
Active, not recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia, Europe and North America. The aim of the trial is to evaluate safety, efficacy and pharmacokinetics (the exposure of the trial drug in the body) of NNC-0156-0000-0009 (nonacog beta pegol, N9-GP) in previously treated children with Haemophilia B.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S